CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Top Cited Papers
Open Access
- 31 October 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (47), eabc9450
- https://doi.org/10.1126/sciadv.abc9450
Abstract
Harnessing CRISPR-Cas9 technology for cancer therapeutics has been hampered by low editing efficiency in tumors and potential toxicity of existing delivery systems. Here, we describe a safe and efficient lipid nanoparticle (LNP) for the delivery of Cas9 mRNA and sgRNAs that use a novel amino-ionizable lipid. A single intracerebral injection of CRISPR-LNPs against PLK1 (sgPLK1-cLNPs) into aggressive orthotopic glioblastoma enabled up to similar to 70% gene editing in vivo, which caused tumor cell apoptosis, inhibited tumor growth by 50%, and improved survival by 30%. To reach disseminated tumors, cLNPs were also engineered for antibody-targeted delivery. Intraperitoneal injections of EGFR-targeted sgPLK1-cLNPs caused their selective uptake into disseminated ovarian tumors, enabled up to similar to 80% gene editing in vivo, inhibited tumor growth, and increased survival by 80%. The ability to disrupt gene expression in vivo in tumors opens new avenues for cancer treatment and research and potential applications for targeted gene editing of noncancerous tissues.Funding Information
- ICRF (2016/iL)
This publication has 51 references indexed in Scilit:
- Development and Applications of CRISPR-Cas9 for Genome EngineeringCell, 2014
- Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteinsGenome Research, 2014
- Genome editing with Cas9 in adult mice corrects a disease mutation and phenotypeNature Biotechnology, 2014
- Evolution of acquired resistance to anti-cancer therapyJournal of Theoretical Biology, 2014
- High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cellsNature Biotechnology, 2013
- Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient OutcomesInternational Journal of Gynecologic Cancer, 2012
- Biodistribution of Small Interfering RNA at the Organ and Cellular Levels after Lipid Nanoparticle-mediated DeliveryJournal of Histochemistry & Cytochemistry, 2011
- In vivo genome editing restores haemostasis in a mouse model of haemophiliaNature, 2011
- Development of a novel mouse glioma model using lentiviral vectorsNature Medicine, 2009
- Intraperitoneal chemotherapy in the management of ovarian cancerCancer, 1993